Cart
sales@molnova.com
K-777
CAS No. 749860-43-3
K-777( K 777 | K777 )
Catalog No. M15857 CAS No. 749860-43-3
K-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameK-777
-
NoteResearch use only, not for human use.
-
Brief DescriptionK-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively.
-
DescriptionK-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively; induces CCR4 internalization, reduces cell surface CCR4.
-
In Vitro——
-
In Vivo——
-
SynonymsK 777 | K777
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number749860-43-3
-
Formula Weight641.5
-
Molecular FormulaC28H32F4IN5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name1-(1-(4-((2,4-difluorobenzyl)amino)-5-(2,4-difluorophenyl)pyrimidin-2-yl)piperidin-4-yl)-1-methylpiperidin-1-ium
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sato T, et al. Pharmacology. 2013;91(5-6):305-13.
2. Solari R, et al. Eur J Pharmacol. 2015 Sep 15;763(Pt B):169-77.
molnova catalog
related products
-
C-021
C-021 is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively.
-
LY-2510924
LY-2510924 (LY2510924)?is a potent and selective, cyclic peptide CXCR4 antagonist with IC50 of 0.079 nM.
-
BX471 hydrochloride
BX471 is a potent, selective, orally available CCR1 antagonist with Ki of 1 nM for hCCR1, displays 100 times less affinity for rat CCR1.
